Investment Analysts’ Weekly Ratings Updates for Damora Therapeutics, Inc. Common Stock (DMRA)

A number of firms have modified their ratings and price targets on shares of Damora Therapeutics, Inc. Common Stock (NASDAQ: DMRA) recently:

• 6/12/2026 – Damora Therapeutics, Inc. Common Stock had its “outperform” rating reaffirmed by Wedbush. They now have a $35.00 price target on the stock.
• 6/11/2026 – Damora Therapeutics, Inc. Common Stock is now covered by HC Wainwright. They set a “buy” rating and a $45.00 price target on the stock.
• 6/8/2026 – Damora Therapeutics, Inc. Common Stock is now covered by TD Cowen. They set a “buy” rating on the stock.
• 5/28/2026 – Damora Therapeutics, Inc. Common Stock is now covered by Wedbush. They set an “outperform” rating and a $35.00 price target on the stock.
• 4/24/2026 – Damora Therapeutics, Inc. Common Stock is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $40.00 price target on the stock.
• 4/23/2026 – Damora Therapeutics, Inc. Common Stock was upgraded by Royal Bank Of Canada to “moderate buy”.

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.